The Mitigate study by Kaiser has 16,000 randomized patients taking 4 grams/day of Vascepa... Mitigate is presently studying Covid for reduction in the same types of outcomes as previously studied in Cardiolink....which had statistically positive results for reductions in hospitalizations and deaths, and Prepare It, which was trending positive...when the money ran out to continue the study over a longer time period...i.e.in order to achieve the probable result of statistical significance.
Mitigate, which was commenced in August of 2020 has signified its primary completion to be date-Feb 2022...and its final completion date to be Feb-2023.
Stay tuned!...With Covid on the March, the Mitigate Cavalry could be called upon to join the Covid battle.
News 
Market Data 
Discover 
